15:58 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Rat studies suggest GDNF-secreting human retinal epithelial cells could help treat epilepsy. In a rat model of pilocarpine-induced epilepsy, bilateral intrahippocampal implantation of GDNF-secreting human retinal epithelial cells decreased behavioral and cognitive impairments...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR...
07:00 , Mar 9, 2015 |  BioCentury  |  Emerging Company Profile

AAVs for the CNS

Voyager Therapeutics Inc. has a pipeline of adeno-associated viral vector-based gene therapies and is developing novel vectors that are optimized for better distribution in the CNS, among other qualities. Third Rock Ventures launched Voyager about...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I started

uniQure said researchers at the University of California , San Francisco and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) began an open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF in about 24...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I start

Next month, researchers at the University of California (San Francisco, Calif.) and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) will begin an open-label Phase I trial to evaluate AAV2-GDNF in about 24...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Amsterdam Molecular, uniQure deal

Amsterdam Molecular's board unanimously recommended dissolving the company's assets into newco uniQure in a stock deal. Amsterdam said it is facing a "precarious" financial position with cash expected to last until April and the deal...
01:40 , Feb 18, 2012 |  BC Extra  |  Company News

Amsterdam Molecular to transfer assets, delist

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) said its board unanimously recommended dissolving the company's assets into newly formed uniQure B.V. (Amsterdam, the Netherlands) in a stock deal. Amsterdam said it is facing a "precarious" financial...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...